JAK

Janus kinase

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

(2R,5S)-Ritlecitinib

((2R,5S)-PF-06651600)

Cat. No.: HY-100754B

(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective **JAK3** inhibitor (IC_{50}=144.8 nM) extracted from patent US20150158864A1, example 68.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg

(3R,4S)-Tofacitinib

Cat. No.: HY-40354D

(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3S,4R)-Tofacitinib

Cat. No.: HY-40354B

(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3S,4S)-Tofacitinib

Cat. No.: HY-40354C

(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 1 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42)

Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib

((E/Z)-TG02; (E/Z)-SB1317)

Cat. No.: HY-15166

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3**. (E/Z)-Zotiraciclib ((E/Z)-TG02) can be used for the research of cancer.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib citrate

((E/Z)-TG02 citrate; (E/Z)-SB1317 citrate)

Cat. No.: HY-15166B

(E/Z)-Zotiraciclib citrate is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib hydrochloride

((E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride)

Cat. No.: HY-15166A

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-Ruxolitinib-d9

((Rac)-INCB18424-d9)

Cat. No.: HY-W062703S

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide

Cat. No.: HY-120469

GDC-046 is a potent, selective, and orally bioavailable **TYK2** inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Abrocitinib

(PF-04965842) Cat. No.: HY-107429

Abrocitinib (PF-04965842) is a potent, orally active and selective **JAK1** inhibitor, with **IC_{50}**s of 29 and 803 nM for JAK1 and JAK2, respectively.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an **IC_{50}** of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with **IC_{50}**s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (**IC_{50}**s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZ-3

Cat. No.: HY-112442

AZ-3 is a potent and selective **JAK1** inhibitor with an **IC_{50}** of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ960

Cat. No.: HY-10411

AZ960 is a potent and specific inhibitor of the **JAK2** kinase with a **K_i** of 0.45 nM.



Purity: 97.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZD-1480

Cat. No.: HY-10193

AZD-1480 is an ATP-competitive inhibitor of **JAK1** and **JAK2** with **IC_{50}**s of 1.3 nM and <0.4nM, respectively.



Purity: 99.37%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Baricitinib

(LY3009104; INCB028050) Cat. No.: HY-15315

Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with **IC_{50}**s of 5.9 nM and 5.7 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib phosphate

(LY3009104 phosphate; INCB028050 phosphate) Cat. No.: HY-15315A

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable **JAK1**/**JAK2** inhibitor with **IC_{50}** of 5.9 nM and 5.7 nM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib-d3

(LY3009104-d3; INCB028050-d3) Cat. No.: HY-15315S1

Baricitinib-d3 (LY3009104-d3) is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with IC_{50}s of 5.9 nM and 5.7 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Baricitinib-d5

(LY3009104-d5; INCB028050-d5) Cat. No.: HY-15315S

Baricitinib-d5 (LY3009104-d5) is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with IC_{50}s of 5.9 nM and 5.7 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BD750

Cat. No.: HY-131140

BD750, an effective immunosuppressant and a **JAK3/STAT5** inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC_{50} values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-066

Cat. No.: HY-18710

BMS-066 is an **IKKβ/Tyk2** pseudokinase inhibitor, with IC_{50}s of 9 nM and 72 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-911543

Cat. No.: HY-15270

BMS-911543 is a selective **JAK2** inhibitor, with IC_{50}s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC_{50}, 75, 360, 66 nM, respectively).



Purity: 98.05%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986202

Cat. No.: HY-131968

BMS-986202 is a potent, selective and orally active **Tyk2** inhibitor that binds to **Tyk2 JH2** with an IC_{50} of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members.



Purity: 99.46%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brepocitinib

(PF-06700841) Cat. No.: HY-112708

Brepocitinib (PF-06700841) is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with IC_{50}s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Brepocitinib P-Tosylate

(PF-06700841 P-Tosylate) Cat. No.: HY-112708A

Brepocitinib (PF-06700841) P-Tosylate is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with IC_{50}s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brevilin A

Cat. No.: HY-N2959

Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of **JAK-STAT** signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC_{50} = 10.6 μM) in Cancer Cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CEP-1347

(KT7515) Cat. No.: HY-10412

CEP-1347 is an inhibitor of the **JNK/SAPK** pathway with neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

CEP-33779

Cat. No.: HY-15343

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of **JAK2** with an IC_{50} of 1.8±0.6 nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cerdulatinib

(PRT062070; PRT2070)

Cat. No.: HY-15999

Cerdulatinib (PRT062070) is a selective **Tyk2** inhibitor with an IC_{50} of 0.5 nM. Cerdulatinib (PRT062070) also is a dual **JAK** and **SYK** inhibitor with IC_{50}s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.



Purity: 99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cerdulatinib hydrochloride

(PRT062070 hydrochloride; PRT2070 hydrochloride)

Cat. No.: HY-15999A

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual **SYK** and **JAK**, with IC_{50}s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for **SYK** and **Tyk2**, **JAK1**, **2**, **3**, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHZ868

Cat. No.: HY-18960

CHZ868 is a type II **JAK2** inhibitor with an IC_{50} of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coumermycin A1

Cat. No.: HY-N7452

Coumermycin A1 is a **JAK2 signal** activator. Coumermycin A1 inhibits **DNA Gyrase** which thereby inhibits cell division in bacteria.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Cucurbitacin I

(Elatericin B; JSI-124; NSC-521777)

Cat. No.: HY-N1405

Cucurbitacin I is a natural selective inhibitor of **JAK2/STAT3**, with potent anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Curculigoside

Cat. No.: HY-N0705

Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the **JAK/STAT/NF-κB** signaling pathway.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decernotinib

(VX-509; VRT-831509)

Cat. No.: HY-12469

Decernotinib is a potent, orally active **JAK3** inhibitor, with K_is of 2.5, 11, 13 and 11 nM for **JAK3**, JAK1, JAK2, and TYK2, respectively.



Purity: 99.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Dehydrocrenatidine

(Kumujian G; O-Methylpicrasidine I)

Cat. No.: HY-N3710

Dehydrocrenatidine, a natural alkaloid, is a specific **JAK** inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Delgocitinib

(JTE-052)

Cat. No.: HY-109053

Delgocitinib (JTE-052) is a specific **JAK** inhibitor with **IC_{50}**s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delphinidin chloride

Cat. No.: HY-N2409

Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deucravacitinib

(BMS-986165)

Cat. No.: HY-117287

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric **TYK2** inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (**IC_{50}**=1.0 nM) and blocks receptor-mediated Tyk2 activation by...



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Deuruxolitinib

(CTP-543; Ruxolitinib D8; Deuterated Ruxolitinib)

Cat. No.: HY-50856S

Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DTP3

Cat. No.: HY-100538

DTP3 TFA is a potent and selective **GADD45β/MKK7** inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fedratinib

(TG-101348; SAR 302503)

Cat. No.: HY-10409

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active **JAK2** inhibitor with **IC_{50}**s of 3 nM for both **JAK2** and **JAK2V617F kinase**. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg, 200 mg, 500 mg, 1 g

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate)

Cat. No.: HY-10409A

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active **JAK2** inhibitor with **IC_{50}**s of 3 nM for both **JAK2** and **JAK2V617F kinase**.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg, 200 mg, 500 mg, 1 g

Filgotinib

(GLPG0634)

Cat. No.: HY-18300

Filgotinib (GLPG0634) is a selective and orally active **JAK1** inhibitor with **IC_{50}** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Filgotinib-d4

(GLPG0634-d4)

Cat. No.: HY-18300S

Filgotinib-d4 (GLPG0634-d4) is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective **JAK1** inhibitor with **IC_{50}** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

FLLL32

Cat. No.: HY-100544

FLLL32, a synthetic analog of curcumina, is a **JAK2/STAT3** dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FM-381

Cat. No.: HY-102046

FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909. FM-381 has an IC_{50} of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FM-479

Cat. No.: HY-131014

FM-479 is the **negative control** of FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fosifidancitinib

Cat. No.: HY-109175

Fosifidancitinib is a potent and selective inhibitor of **JAK kinases 1/3**. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G5-7

Cat. No.: HY-115452

G5-7, an orally active and allosteric **JAK2** inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr^{1068}) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Gandotinib

(LY2784544)

Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GDC-4379

Cat. No.: HY-139837

GDC-4379 is a **JAK1** inhibitor that can be used for the research of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rk1

Cat. No.: HY-N2515

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of **Jak2/Stat3** signaling pathway and **NF-κB**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

GLPG0634 analog

Cat. No.: HY-13961

GLPG0634 (analog) (compound176)is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Golidocitinib

(AZD4205)

Cat. No.: HY-107361

Golidocitinib (AZD4205) is a selective **JAK1** inhibitor, with an IC_{50} of 73 nM, weakly inhibits JAK2 (IC_{50}>14.7 μM), and shows little inhibition on JAK3 (IC_{50}>30 μM).



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gusacitinib

(ASN-002)

Cat. No.: HY-103018

Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (**SYK**) and janus kinase (**JAK**) with IC_{50} values of 5-46 nM. Gusacitinib has anti-cancer activity in both solid and hematological tumor types.



Purity: 99.41%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ifidancitinib

(ATI-50002; ATI-502)

Cat. No.: HY-109178

Ifidancitinib (ATI-50002) is a potent and selective inhibitor of **JAK kinases 1/3**. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib

(NS-018)

Cat. No.: HY-19631A

Ilginatinib (NS-018) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: 99.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib hydrochloride

(NS-018 hydrochloride)

Cat. No.: HY-19631B

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib maleate

(NS-018 maleate)

Cat. No.: HY-19631

Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable **JAK2** inhibitor, with an IC_{50} of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC_{50}, 33 nM), JAK3 (IC_{50}, 39 nM), and Tyk2 (IC_{50}, 22 nM).



Purity: 97.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilunocitinib

Cat. No.: HY-132819

Ilunocitinib (compound 27) is a **JAK** inhibitor (extracted from patent WO2009114512A1).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Itacitinib

(INCB039110)

Cat. No.: HY-16997

Itacitinib (INCB039110) is an orally active and selective inhibitor of **JAK1** with an IC_{50} of 2 nM for **human JAK1**. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Itacitinib adipate

Cat. No.: HY-16997A

Itacitinib adipate is an orally bioavailable and selective **JAK1** inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Itacnosertib

(TP-0184)

Cat. No.: HY-109179

Itacnosertib (TP-0184) is both inhibitor to **JAK2**, **ACVR1 (ALK2)** and **ALK5** as described in WO2014151871.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Izencitinib

(TD-1473; JNJ-8398)

Cat. No.: HY-109148

Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted **JAK** inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

JAK-2/3-IN-1

Cat. No.: HY-10652

JAK-2/3-IN-1 is a potent **JAK-2** and **JAK-3** inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-1

Cat. No.: HY-13827

JAK-IN-1 is a **JAK1/2/3** inhibitor with **IC_{50}**s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-10

Cat. No.: HY-U00277

JAK-IN-10 is a **JAK** inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-11

Cat. No.: HY-U00318

JAK-IN-11 is a potent and selective **JAK** inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-14

Cat. No.: HY-139807

JAK-IN-14 is a potent and selective **JAK1** inhibitor, with an **IC_{50}** of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).



Purity: 98.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

JAK-IN-15

Cat. No.: HY-46262

JAK-IN-15 is a **JAK** inhibitor. WO2016119700A1 (Compound 15).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-17

Cat. No.: HY-144057

JAK-IN-17 is a potent inhibitor of **JAK**. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-18

Cat. No.: HY-144058

JAK-IN-18 is a potent inhibitor of **JAK**. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-19

Cat. No.: HY-144075

JAK-IN-19 is a potent **JAK** inhibitor (PBMC IFNγ **pIC_{50}**=7.2 and HLF Eotaxin **pIC_{50}**=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 **pIC_{50}**=7.0, Aurora B **pIC_{50}**=5.8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-20

Cat. No.: HY-143444

JAK-IN-20 is a potent, pan and orally active **JAK** inhibitor with an **IC_{50}**s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-3

Cat. No.: HY-111750

JAK-IN-3 (compound 22) is a potent **JAK** inhibitor, with IC_{50} values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-IN-4

Cat. No.: HY-111749

JAK-IN-4 is a prodrug of a **JAK** inhibitor, effective in murine collagen induced arthritis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-5

Cat. No.: HY-111471

JAK-IN-5 is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-IN-5 hydrochloride

Cat. No.: HY-111471A

JAK-IN-5 hydrochloride is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK/HDAC-IN-1

Cat. No.: HY-126141

JAK/HDAC-IN-1 is a potent **JAK2/HDAC** dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC_{50}s of 4 and 2 nM for JAK2 and HDAC, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JAK1-IN-4

Cat. No.: HY-116505

JAK1-IN-4 is a potent and selective **JAK1** inhibitor, with IC_{50}s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC_{50}, 227 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1-IN-7

Cat. No.: HY-126294

JAK1-IN-7 is a **Janus-associated kinase 1 (JAK1)** inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1-IN-8

Cat. No.: HY-139423

JAK1-IN-8, a potent **JAK1** inhibitor (IC_{50}<500 nM), compound 28, extracted from patent WO2016119700A1.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK1-IN-9

Cat. No.: HY-144440

JAK1-IN-9 (compound 23a) is a potent and selective **JAK1** inhibitor with an IC_{50} of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1/TYK2-IN-1

Cat. No.: HY-145336

JAK1/TYK2-IN-1 is a dual inhibitor of **TYK2** and **JAK1** (IC_{50} = 29 and 41 nM respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1/TYK2-IN-3

Cat. No.: HY-143885

JAK1/TYK2-IN-3 is a potent, selective and orally active dual **TYK2/JAK1** inhibitor with IC_{50} values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to **JAK2** (IC_{50}=140 nM) and **JAK3** (IC_{50}=362 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-4

Cat. No.: HY-100759

JAK2-IN-4 (compound 16h) is a selective **JAK2/JAK3** inhibitor, with IC_{50} values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-6

Cat. No.: HY-137756

JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective **JAK2** inhibitor with an IC_{50} of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-7

Cat. No.: HY-131906

JAK2-IN-7 is a selective **JAK2** inhibitor with IC_{50}s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3^{V617F} cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK2/FLT3-IN-1

Cat. No.: HY-130247

JAK2/FLT3-IN-1 is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2/FLT3-IN-1 TFA

Cat. No.: HY-130247A

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JAK2/TYK2-IN-1

Cat. No.: HY-143884

JAK2/TYK2-IN-2 is a potent and selective **TYK2** inhibitor with IC_{50} values of 9 and 157 nM for **TYK2** and **JAK2**, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3 covalent inhibitor-1

Cat. No.: HY-119935

JAK3 covalent inhibitor-1 is a potent and selective **janus kinase 3 (JAK3)** covalent inhibitor with an IC_{50} of 11 nM and shows 246-fold selectivity vs other JAKs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3-IN-1

Cat. No.: HY-19544

JAK3-IN-1 is a potent, selective and orally active **JAK3** inhibitor with an IC_{50} of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for **JAK3** than JAK1 (IC_{50} of 896 nM) and JAK2 (IC_{50} of 1050 nM).



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JAK3-IN-11

Cat. No.: HY-146727

JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active **JAK3** inhibitor with IC_{50} value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3-IN-6

Cat. No.: HY-101976

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC_{50} of 0.15 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JAK3-IN-7

Cat. No.: HY-U00390

JAK3-IN-7 is a potent and selective **JAK3** inhibitor extracted from patent WO2011013785A1, has an IC_{50} of <0.01 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-1

Cat. No.: HY-143716

JAK3/BTK-IN-1 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-2

Cat. No.: HY-143717

JAK3/BTK-IN-2 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-3

Cat. No.: HY-143718

JAK3/BTK-IN-3 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-4

Cat. No.: HY-143719

JAK3/BTK-IN-4 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-5

Cat. No.: HY-143720

JAK3/BTK-IN-5 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JANEX-1

(WHI-P131; Jak3 inhibitor I)

Cat. No.: HY-15508

JANEX-1 (WHI-P131) is a potent and specific **JAK3** inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC_{50} of 78 μM), does not inhibit JAK1 and JAK2.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

LFM-A13

Cat. No.: HY-18009

LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC_{50}s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lorpucitinib

(JNJ-64251330) Cat. No.: HY-109182

Lorpucitinib is a Gut-Restricted **JAK** Inhibitor for the research of Inflammatory Bowel Disease.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Momelotinib

(CYT387) Cat. No.: HY-10961

Momelotinib (CYT387) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50}a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.



Purity: 98.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Momelotinib Mesylate

(CYT387 Mesylate) Cat. No.: HY-10963

Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50} of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Momelotinib sulfate

(CYT387 sulfate salt) Cat. No.: HY-10962

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50} of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC_{50}=155 nM).



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nezulcitinib

(TD-0903) Cat. No.: HY-132849

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (**JAK**) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 33994

Cat. No.: HY-18293

NSC 33994 (G6) is a selective **JAK2** inhibitor, with an IC_{50} of 60 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 42834

(JAK2 Inhibitor V; Z3) Cat. No.: HY-15480

NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of **Jak2**, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.



Purity: 96.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805

Cat. No.: HY-14722

NVP-BSK805 is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-BSK805 dihydrochloride

Cat. No.: HY-14722A

NVP-BSK805 dihydrochloride is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805 trihydrochloride

Cat. No.: HY-14722C

NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oclacitinib maleate

(PF-03394197 maleate) Cat. No.: HY-13577A

Oclacitinib maleate (PF-03394197 maleate) is a novel **JAK** inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting **JAK1** (IC_{50}=10 nM).



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pacritinib

(SB1518) Cat. No.: HY-16379

Pacritinib (SB1518) is a potent inhibitor of both wild-type **JAK2** (IC_{50}=23 nM) and **JAK2**^{V617F} mutant (IC_{50}=19 nM). Pacritinib also inhibits **FLT3** (IC_{50}=22 nM) and its mutant **FLT3**^{D835Y} (IC_{50}=6 nM).



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Peficitinib

(ASP015K; JNJ-54781532) Cat. No.: HY-19568

Peficitinib is an oral **JAK** inhibitor, with IC_{50}s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-06263276

Cat. No.: HY-101024

PF-06263276 (PF 6263276) is a potent and selective **pan-JAK** inhibitor, with IC_{50}s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Povorcitinib

Cat. No.: HY-145588

Povorcitinib is a potent and selective inhibitor of **JAK1**. Povorcitinib has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) (extracted from patent WO2021076124A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protosappanin A

(PTA) Cat. No.: HY-113573

Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses **JAK2/STAT3**-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.



Purity: 99.98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Pyridone 6

Cat. No.: HY-14435

Pyridone 6 is a **pan-JAK** inhibitor, which potently inhibits the JAK kinase family, with IC_{50}s of 1 nM for **JAK2** and **TYK2**, 5 nM for **JAK3**, and 15 nM for **JAK1**, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reticuline-d3

Cat. No.: HY-N1356S

Reticuline-d3 is the deuterium labeled Reticuline. Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.07%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ritlecitinib

(PF-06651600)

Cat. No.: HY-100754

Ritlecitinib (PF-06651600) is an orally active and selective **JAK3** inhibitor with an IC_{50} of 33.1 nM.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RO495

Cat. No.: HY-18316

RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (**TYK2** kinase).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8191

(CDM-3008; RO4948191)

Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ruxolitinib

(INCB18424)

Cat. No.: HY-50856

Ruxolitinib (INCB18424) is a potent and selective **JAK1/2** inhibitor with IC_{50}s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces **autophagy** and kills tumor cells through toxic **mitophagy**.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib (S enantiomer)

(S-Ruxolitinib; S-INCB18424)

Cat. No.: HY-50856A

Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is a **JAK** inhibitor.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ruxolitinib phosphate

(INCB018424 phosphate)

Cat. No.: HY-50858

Ruxolitinib phosphate (INCB018424 phosphate) is a potent **JAK1/2** inhibitor with IC_{50}s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib sulfate

(INCB018424 sulfate)

Cat. No.: HY-50859

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective **JAK1/2** inhibitor to enter the clinic with IC_{50}s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

SAR-20347

Cat. No.: HY-100895

SAR-20347 is an inhibitor of **TYK2**, **JAK1**, **JAK2** and **JAK3** with IC_{50}s of 0.6, 23, 26 and 41 nM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC99

Cat. No.: HY-124858

SC99 is an orally active, selective **STAT3** inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SD-1008

Cat. No.: HY-107595

SD-1008 is a potent **JAK** inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances **apoptosis** induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-1029

Cat. No.: HY-112391

SD-1029 is a **JAK2/STAT3** inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHR0302

Cat. No.: HY-112724

SHR0302 is a potent and orally active all members of the **JAK family** inhibitor, particularly **JAK1**. The selectivity of SHR0302 for **JAK1** is >10-fold for **JAK2**, 77-fold for **JAK3**, 420-fold for **Tyk2**.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

SJ10542

Cat. No.: HY-145696

SJ10542 is a potent and selective **JAK2/3** directing phenyl glutarimide (PG)-PROTAC with **DC_{50}**s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Solcitinib

(GSK-2586184; GLPG-0778)

Cat. No.: HY-16755

Solcitinib is an orally active, competitive, potent, selective **JAK1** inhibitor, with an **IC_{50}** of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SYK/JAK-IN-1

Cat. No.: HY-145029

SYK/JAK-IN-1 is dual **SYK/JAK** inhibitor with **IC_{50}**s of <5 nM for SYK and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCJL37

Cat. No.: HY-16640

TCJL37 is a potent, selective, and orally bioavailable **TYK2** inhibitor with a **K_i** of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCS 21311

(NIBR3049)

Cat. No.: HY-108264

TCS 21311 (NIBR3049) is a potent, highly selective **JAK3** inhibitor with an **IC_{50}** of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits **PKCα**, **PKCθ**, and **GSK3β** with **IC_{50}**s of 13, 68, and 3 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Ten01

Cat. No.: HY-139649

Ten01 has 5.0 nM activity against **JAK1** kinase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with **IC_{50}** of 6 nM, less potent to **Flt3** and **RET** with **IC_{50}** of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tofacitinib

(Tasocitinib; CP-690550) Cat. No.: HY-40354

Tofacitinib is an orally available **JAK3/2/1** inhibitor with **IC_{50}**s of 1, 20, and 112 nM, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib citrate

(Tasocitinib citrate; CP-690550 citrate) Cat. No.: HY-40354A

Tofacitinib citrate is an orally available **JAK1/2/3** inhibitor with **IC_{50}**s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib Prodrug-1

Cat. No.: HY-145829

Tofacitinib Prodrug-1 is an effective and oral active prodrug to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib Prodrug-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tofacitinib-13C3

(Tasocitinib-13C3; CP-690550-13C3) Cat. No.: HY-40354S

Tofacitinib-13C3 (Tasocitinib-13C3) is the 13C-labeled Tofacitinib. Tofacitinib is an orally available **JAK3/2/1** inhibitor with **IC_{50}**s of 1, 20, and 112 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tofacitinib-d3 citrate

(Tasocitinib-d3 citrate; CP-690550-d3 citrate) Cat. No.: HY-40354AS

Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TYK2-IN-11

Cat. No.: HY-144087

TYK2-IN-11 (Compound 5B) is a selective **Tyk-2** inhibitor with **IC_{50}**s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TyK2-IN-2

Cat. No.: HY-101762

TyK2-IN-2 (Compoud 18) is a potent and selective **TYK2** inhibitor with **IC_{50}**s of 7 nM, 0.1 μM and 0.05 μM for **TYK2 JH2**, **IL-23** and **IFNα**, respectively. TyK2-IN-2 also inhibits **phosphodiesterase 4 (PDE4)** with an **IC_{50}** of 62 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tyk2-IN-3

Cat. No.: HY-18709

Tyk2-IN-3 is a **Tyk2 pseudokinase** inhibitor, with an **IC_{50}** of 485 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyk2-IN-5

Cat. No.: HY-111745

Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active **Tyk2** inhibitor and targets the JH2 domain, with a **K_i** of 0.086 nM for Tyk2 JH2 and an **IC_{50}** of 25 nM for IFNα.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-7

Cat. No.: HY-126242S

Tyk2-IN-7 (Compound 48) is a **TYK2 JH2** inhibitor, binds to TYK2 JH2 domain with **IC_{50}** and **$K_{i,app}$** of 0.00053 μM and 0.00007 μM, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-8

Cat. No.: HY-144031S

Tyk2-IN-8 (Compound 3) is a selective **Tyk-2** inhibitor with an **IC_{50}** of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC_{50} of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyk2-IN-9

Cat. No.: HY-144032

Tyk2-IN-9 (Compound 26) is a selective **Tyk-2** inhibitor with **IC_{50}**s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Upadacitinib

(ABT-494)

Cat. No.: HY-19569

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (**JAK1**) inhibitor (**IC_{50}**=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with **IC_{50}**s of 4 nM and 1.8 μM, respectively.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P97

Cat. No.: HY-11067

WHI-P97 is a potent and selective **JAK-3** inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WP1066

Cat. No.: HY-15312

WP1066 is an inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

XL019

Cat. No.: HY-13775

XL019 is a potent, orally active, and selective **JAK2** inhibitor, with **IC_{50}**s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ZM39923

Cat. No.: HY-12589A

ZM39923 is a **JAK3** inhibitor, with a **pIC_{50}** of 7.1; ZM39923 also potently inhibits tissue transglutaminase (**TGM2**) with an **IC_{50}** of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZM39923 hydrochloride

Cat. No.: HY-12589

ZM39923 hydrochloride is a **JAK3** inhibitor, with a **pIC_{50}** of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (**TGM2**) with an **IC_{50}** of 10 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

α7 nAchR-JAK2-STAT3 agonist 1

Cat. No.: HY-146066

α7 nAchR-JAK2-STAT3 agonist 1 is a potent **α7 nAchR-JAK2-STAT3** agonist, with an **IC_{50}** value of 0.32 μM for **nitric oxide (NO)**. α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg